These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins AI, AII and B and LCAT activity in hyperlipidemic, non-insulin-dependent diabetics. Prager R; Schernthaner G; Kostner GM; Mühlhauser I; Zechner R; Dorda W Atherosclerosis; 1982 Jun; 43(2-3):321-7. PubMed ID: 6810904 [TBL] [Abstract][Full Text] [Related]
8. Dose-response study of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinanemia. Olsson AG; Lang PD Atherosclerosis; 1978 Dec; 31(4):421-8. PubMed ID: 215174 [TBL] [Abstract][Full Text] [Related]
9. [Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia]. Arntz HR; Klemens UH; Vollmar LJ; Lang PD Med Klin; 1978 Dec; 73(49):1731-7. PubMed ID: 723760 [TBL] [Abstract][Full Text] [Related]
10. Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV. Schwandt P; Weisweiler P Artery; 1980; 7(6):464-70. PubMed ID: 7236016 [TBL] [Abstract][Full Text] [Related]
11. Effects of bezafibrate on the serum lipoprotein lipid and apolipoprotein composition, lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters. Vessby B; Lithell H; Hellsing K; Ostlund-Lindqvist AM; Gustafsson IB; Boberg J; Ledermann H Atherosclerosis; 1980 Oct; 37(2):257-69. PubMed ID: 7000090 [No Abstract] [Full Text] [Related]
12. Effects of bezafibrate on the composition of very low density lipoproteins in type IV hyperlipoproteinemia. Schwandt P; Weisweiler P; Drosner M; Janetschek P Atherosclerosis; 1982 Apr; 42(2-3):245-9. PubMed ID: 7073803 [No Abstract] [Full Text] [Related]
13. [Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias]. Machalke K; Djaja S; Richter E Ther Ggw; 1982 May; 121(5):301-11. PubMed ID: 6953613 [No Abstract] [Full Text] [Related]
14. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia. Kłosiewicz-Latoszek L; Szostak WB Eur J Clin Pharmacol; 1991; 40(1):33-41. PubMed ID: 2060543 [TBL] [Abstract][Full Text] [Related]
15. The effect of etofibrate retard, bezafibrate and procetofen. Luley C; Schwartzkopff W; Schilling A; Calder D; Scheffler W Artery; 1980; 8(2):128-33. PubMed ID: 7458677 [TBL] [Abstract][Full Text] [Related]
16. Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects. Stewart JM; Packard CJ; Lorimer AR; Boag DE; Shepherd J Atherosclerosis; 1982 Sep; 44(3):355-65. PubMed ID: 6293516 [TBL] [Abstract][Full Text] [Related]
17. [Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb]. Kokot F; Szczechowska E Z Gesamte Inn Med; 1981 Jul; 36(13):454-7. PubMed ID: 7025475 [TBL] [Abstract][Full Text] [Related]
19. [Improvement in diabetes control by treatment with bezafibrate]. Rüth E; Vollmar J Dtsch Med Wochenschr; 1982 Oct; 107(39):1470-3. PubMed ID: 6749468 [TBL] [Abstract][Full Text] [Related]
20. One-year study of the effect of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemia. Olsson AG; Lang PD Atherosclerosis; 1978 Dec; 31(4):429-33. PubMed ID: 215175 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]